Replies to post #338486 on Amarin Corp Plc (AMRN)

[Number sleven]

Bill, That in my mind is the question. The scope of the arguments was narrowed. The other issues in the case still remain. The court just reffed to them as fully briefed. The wording in the ruling should provide some benefit to Amarin's case.(assuming GSK wins) How much depends on the words. Yes. Regardless of the ruling, this will almost certainly be appealed. The ruling will stand during the appeal process.(my understanding) Will we have this ruling by the 26th? Will the judge in our case be interested in a dismissal without seeing that ruling? If we get past the dismissal I think Hikma is taking a lot of risk for little reward.
My (non lawyer) opinion.
Sleven,

[sts66]

Appealed to whom? The SC is the only court left after this decision - they don't get to ask for another en banc review after already being denied one AFAIK.